Novartis announces clinical collaboration with Pfizer to advance the treatment of NASH
- Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH)
- Novartis has a leading development portfolio in non-viral liver diseases, including NASH
- There are currently no approved treatments for NASH, a progressive?form of non-alcoholic fatty liver disease, which affects up to 6.5% of the population worldwide[1],-[2]
# # #
Novartis Media Relations Central media line: +41 61 324 2200 E-mail: media.relations@novartis.comEric Althoff Novartis Global Media Relations +41 61 324 7999 (direct) +41 79 593 4202 (mobile) eric.althoff@novartis.com | Friedrich von Heyl Novartis Global Pharma Communications +41 61 324 8984 (direct) +41 79 749 0286 (mobile) friedrich.vonheyl@novartis.com |